HD-OPM Archive
Hashtags

#csl112

3 posts

HDL and ApoA-I raising therapies repeatedly failed, so HDL is probably not directly causal

Mar 11, 2024 · Louis Nervegna ♥ 6 · 💬 9 ↩ 22 LDL, ApoB & lipid panel

Louis reviews why HDL or ApoA-I is probably not causal for heart disease. CETP inhibitor trials failed (ILLUMINATE with torcetrapib was stopped for harm; dal-OUTCOMES with dalcetrapib and ACCELERATE with evacetrapib showed no benefit), as did fibrate and niacin trials and CSL112 infusions, and Mendelian randomization agrees. He proposes HDL and ApoA-I mainly act as a proxy for insulin sensitivity, which is the real causal factor.

CSL112 ApoA-I infusion failed in phase 3 AEGIS-II, supporting HDL as marker not cause

Feb 13, 2024 · Louis Nervegna ♥ 8 · 💬 5 ↩ 14 LDL, ApoB & lipid panel

Louis argues the failure of AEGIS-II, in which patients received native ApoA-I (CSL112), shows ApoA-I is not directly causal in heart disease. Every large pharmaceutical trial raising HDL or ApoA-I has failed to prevent heart attacks and strokes. HDL and ApoA-I remain good risk markers, probably standing in for insulin resistance, so raising them by means other than improving insulin sensitivity may not lower risk.